[Treatment of respiratory syncytial virus infections in immunocompromised hematological patients].
Respiratory syncytial virus (RSV) accounts for considerable morbidity among infants and elderly, that are otherwise immunocompetent. Immunocompromised haematological patients--in particular bone marrow transplant (BMT) recipients with leukopenia--are at high risk for severe, usually fatal, RSV-pneumonia. No randomized, placebo-controlled studies of aerosolized ribavirin for BMT patients with RSV-pneumonia have been conducted, or can be anticipated. We summarize existing case reports providing circumstantial evidence in favour of an active diagnostic and early therapeutic approach to these patients.
Thorsen
S
S
H:S Rigshospitalet, klinisk mikrobiologisk afdeling.
Hornsleth
A K
AK
Pedersen
B K
BK
Heilmann
C J
CJ
D000336:Aerosols; D000368:Aged; D000998:Antiviral Agents / Q000008:administration & dosage; D016026:Bone Marrow Transplantation / Q000009:adverse effects / Q000276:immunology; D006801:Humans; D016867:Immunocompromised Host; D007223:Infant; D007970:Leukopenia / Q000276:immunology; D011024:Pneumonia, Viral / Q000188:drug therapy / Q000276:immunology; D018357:Respiratory Syncytial Virus Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D012254:Ribavirin / Q000008:administration & dosage; D012307:Risk Factors
D000336:Aerosols; D000998:Antiviral Agents; D012254:Ribavirin